Education
About Us
Working with TipRanks
Follow Us
Towa Pharmaceutical Co Ltd (TWAPF)
OTHER OTC:TWAPF
TWAPF Stock Chart & Stats
$25.33
$0.00(0.00%)
At close: 4:00 PM EST
$25.33
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$16.23 - $25.33
Previous CloseN/A
Volume1.00
Average Volume (3M)0.00
Market Cap
$1.37B
Enterprise Value$401.83B
Total Cash (Recent Filing)$39.82B
Total Debt (Recent Filing)$233.66B
Price to Earnings (P/E)8.8
Beta0.36
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.18%
Share Statistics
EPS (TTM)1.16
Shares Outstanding51,516,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.40
Price to Book (P/B)0.77
Price to Sales (P/S)0.51
P/FCF Ratio-24.72
Enterprise Value/Market Cap292.86
Enterprise Value/Revenue1.49
Enterprise Value/Gross Profit4.05
Enterprise Value/Ebitda8.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.46
Revenue Forecast (FY)$1.79B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained top-line growth indicates continued demand for the company’s generic portfolio and effective product launches. For the next 2–6 months, higher recurring sales improve revenue visibility, support scale advantages in manufacturing, and underwrite operating leverage if sustained.
Margin RecoveryA material rebound in operating and net margins shows improved cost control and pricing execution. This lift restores profitability resilience, improves cash generation potential if maintained, and supports returns on capital over the medium term versus the 2023 trough.
In-house ManufacturingOwning manufacturing and regulatory capabilities provides durable advantages in supply reliability, speed-to-market for generics, and cost control. These in-house functions help sustain margins and reduce third-party dependency across multiple therapeutic areas.
Bears Say
High LeverageElevated leverage constrains financial flexibility and increases interest and refinancing risk. With substantial outstanding debt relative to equity, the company may face limited capacity to invest or absorb shocks, making deleveraging a multi-quarter structural task.
Weak Cash ConversionInconsistent conversion of earnings to free cash flow weakens the company’s ability to retire debt, fund capex, or increase shareholder returns. Modest FCF amid past negative years heightens risk that earnings gains won't quickly translate into durable financial flexibility.
Structural Margin PressureA persistent step-down in gross margin versus earlier years suggests ongoing pricing or cost-pressure in the generics market. Structural margin compression limits long-term operating leverage and caps potential returns even if revenue and volumes grow.
Towa Pharmaceutical Co News
TWAPF FAQ
What was Towa Pharmaceutical Co Ltd’s price range in the past 12 months?
Towa Pharmaceutical Co Ltd lowest stock price was $16.23 and its highest was $25.33 in the past 12 months.
What is Towa Pharmaceutical Co Ltd’s market cap?
Towa Pharmaceutical Co Ltd’s market cap is $1.37B.
When is Towa Pharmaceutical Co Ltd’s upcoming earnings report date?
Towa Pharmaceutical Co Ltd’s upcoming earnings report date is May 14, 2026 which is in 71 days.
How were Towa Pharmaceutical Co Ltd’s earnings last quarter?
Towa Pharmaceutical Co Ltd released its earnings results on Feb 13, 2026. The company reported $1.156 earnings per share for the quarter, beating the consensus estimate of N/A by $1.156.
Is Towa Pharmaceutical Co Ltd overvalued?
According to Wall Street analysts Towa Pharmaceutical Co Ltd’s price is currently Overvalued.
Does Towa Pharmaceutical Co Ltd pay dividends?
Towa Pharmaceutical Co Ltd pays a Semiannually dividend of $0.254 which represents an annual dividend yield of 3.18%. See more information on Towa Pharmaceutical Co Ltd dividends here
What is Towa Pharmaceutical Co Ltd’s EPS estimate?
Towa Pharmaceutical Co Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Towa Pharmaceutical Co Ltd have?
Towa Pharmaceutical Co Ltd has 51,516,000 shares outstanding.
What happened to Towa Pharmaceutical Co Ltd’s price movement after its last earnings report?
Towa Pharmaceutical Co Ltd reported an EPS of $1.156 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Towa Pharmaceutical Co Ltd?
Currently, no hedge funds are holding shares in TWAPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Towa Pharmaceutical Co Ltd
Towa Pharmaceutical Co., Ltd., together with its subsidiaries, researches, develops, produces, and sells ethical drugs, active pharmaceutical ingredients, and intermediates in Japan. The company provides its products in the therapeutic areas of diabetes, digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products. It had a portfolio of approximately 700 drug products. Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
Technical Analysis
Kaken Pharmaceutical Co
―
Kissei Pharmaceutical Co
―
Mochida Pharmaceutical Co., Ltd.
―
KYORIN Pharmaceutical Co.,Ltd.
―
SAWAI GROUP HOLDINGS Co., Ltd.
―
Ownership Overview
―
Insiders
7.71% Mutual Funds
― Other Institutional Investors
88.43% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---